drugset / Trial / NCT07343960
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
Timeline
- Start
- 2026-01-06
- Primary completion
- 2026-11-11
- Completion
- 2026-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capivasertib | Small molecule | — | Oral |
Indications
No indication recorded.